Skip to main content
Oxfordshire Children's Diabetes Service

Alert Coronavirus / COVID-19

If you have a new continuous cough, a high temperature, or a loss or change to your sense of taste or smell, do not come to our hospitals. Follow the national advice on coronavirus (COVID-19).

Please find information on our services and visiting restrictions in our COVID-19 section.

Please see our latest guidance on face masks.

This site is best viewed with a modern browser. You appear to be using an old version of Internet Explorer.


Our Diabetes Research Team would like to thank everybody who is taking part in our research trials, your help is greatly appreciated.

If you are interested in taking part, or are interested in receiving more information on our trials, please contact the Diabetes Research Nurses.

  • Tel: 01865 234905 / 01865 231674

Research is an important part of our work, and ensures we have the evidence we need to make improvements in treatments and services and to deliver better care.

All the medicines we have today, including those used to treat diabetes, are available because scientists and doctors have worked together to discover and develop new treatments through research.

People being cared for today benefit from past research and continue to benefit from research that is currently being carried out.

Diabetes research would not be possible without the support of people with diabetes. By taking part in research you could play an important role in helping to prevent diabetes, to develop new and better treatments, or to find a potential cure.

We are currently recruiting to the following studies.

ADDRESS 2 study

ADDRESS 2 logoThe purpose of this study is to identify newly diagnosed children and adults who want to hear about opportunities to take part in clinical research in the future.

Participants can then be directed towards suitable trials of new treatments, or other studies that they may wish to take part in.

In addition, information and an optional blood sample are collected from participants to understand more about the development and progression of Type 1 diabetes.

The project is being run by a team of researchers at Imperial College London, together with local research teams at numerous sites across England and Wales.

The study is funded by Diabetes UK and JDRF.

Barts Oxford Family Study (BOX)

Barts Oxford Family Study (BOX)We approach all newly diagnosed patients and their families about this study.

The main aim is to find out how type 1 diabetes occurs, and to stop it happening in the future.

Close relatives share some of the same genes and live in the same environment as the child who has developed type 1 diabetes; studying all members of the family is therefore important in understanding why and how diabetes develops.

Studying answers and samples from people with and without diabetes in the same families over time may enable researchers to work out why some people develop this condition while others do not.

The Box Study is funded primarily from Diabetes UK and co-ordinated by a team at the University of Bristol.

Fat and Protein Study

Fat and Protein StudyThis is a local study to look at whether insulin dose adjustment based on fat and protein in food can achieve better blood glucose control after eating high fat and protein meals in children and adolescents using multiple daily injection therapy.

Participants are aged 6-17 years, have been diagnosed over one year and using multiple daily injections. They will be asked to wear a continuous glucose monitor for one week during which they will consume the set study meal on three evenings, each with a calculated dose of insulin given in three different ways (all before the meal, or as a split dose given as two injections).

Findings will help us better understand the effect of fat and protein in food on blood glucose levels and how we can give insulin more effectively to keep BG levels in range after eating.

The project is being led by Dr Julie Edge and Anne Marie Frohock, Dietitian.

Ongoing studies

Adolescent Diabetes Intervention Trial (AdDIT)

AdDIT logoThis is an international multi-centre study looking at the prevention of long-term complications, particularly heart, kidney and circulatory problems.

It is a randomised, double-blind, placebo-controlled trial using an ace inhibitor and / or statin, when compared to a placebo, in teenagers at the top end of the normal range of urinary albumin excretion.

Many of our teenagers also took part in this study as part of the non-intervention (control) arm.

The study received funding from JDRF, DUK and the British Heart Foundation, and is being coordinated by a team at the University of Cambridge.

C-PepTiD study

C-PepTiD study logoThe evaluation of a novel method that measures beta-cell function by dried blood spots in children and adolescents with a recent diagnosis of Type 1 diabetes.

The study aims to evaluate dried blood spots for measuring C-peptide by comparing serum C-peptide results with dried blood spots. This new method of assessing C-peptide could be used in future intervention trials aimed at preserving ß-cell function.

This study is sponsored by Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge, and is jointly funded by the Biomedical Research Centre and Wellcome Trust and UK Novo Nordisk Research Foundation.

Subcutaneous Insulin: Pumps versus Injections (SCIPI)

SCIPI logoThis study aims to compare two methods of insulin delivery, multiple daily injections and pumps in newly diagnosed children to identify which treatment gives better glycaemic control and better quality of life in participants and their families in the first year post diagnosis.

The study is multi sited and is being co-ordinated by Alder Hey Hospital and the University of Liverpool.

Pneumococcal Immunisation Study

This study is looking at the effectiveness of immunising children with diabetes against pneumococcal infection. At present in the UK older children with diabetes are given a vaccine called Pneumovax, but there is some evidence that another pneumococcal vaccine, Prevenar (PCV13) gives better protection.

Future studies

In the future, we plan to be involved in some very exciting new national immunotherapy trials.

These immunotherapy trials aim to reduce the damage to the insulin-making beta cells caused by the immune system in Type 1 newly-diagnosed children, thereby preserving the body's ability to make its own insulin. If successful, certain therapies could also potentially be used to delay the onset of Type 1 diabetes in high risk individuals and hopefully eventually lead to prevention.

In addition we are also planning to be involved in a study looking at new technology in children newly diagnosed with Type 1 diabetes.

If you are interested in taking part in clinical trials in other specialties, please also see: